Edesa Biotech is trading 22.26% down at $4.47 after falling sharply from its August 19 regular-session close; no reliable company-specific announcement or late-breaking catalyst explaining the after-hours decline was identified.
- Latest confirmed company news was fiscal third-quarter results released August 13.
- Prior coverage discussed Phase 2 vitiligo-trial preparations rather than an August 19 event.
- The broader market was modestly higher and does not clearly explain the drop.